Category Archives: Advisory Committee Prepapartion

Approvals in the Crazy Year of 2020

Each year in January, it is relevant to look back on the activities of FDA during the course of the previous year and look at how it was the same or different from prior years, and to look at trends … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , | Comments Off on Approvals in the Crazy Year of 2020

FDA AdComm Agenda Covers the Bases

First of all, we are having a bit of a crisis with our crisis. As we appear to be moving into yet another wave of COVID-19 infections, and as research into a vaccine is aggressively underway, we also see serious … Continue reading

Posted in Advisory Committee Prepapartion, COVID19, Current Affairs, FDA Image, FDA Policy | Tagged | Comments Off on FDA AdComm Agenda Covers the Bases

FDA to Hold Virtual AdComm

I don’t usually publish the scheduling of an AdComm with a blog posting. But this one merits one. With fewer than the usual minimum of fifteen days’ notice, FDA has scheduled an FDA Advisory Committee meeting of the Cardiovascular and … Continue reading

Posted in Advisory Committee Prepapartion, FDA Image, FDA Policy | Tagged , , | Comments Off on FDA to Hold Virtual AdComm

Principles for COVID-19 Healthcare Communications – 2 – The Virtual Medical Meeting

Virtually everyone is going virtual. Even in February, which seems like a very long time ago, many organizers began either postponing or canceling major conferences and meetings. This has included major medical meetings and given that large gatherings will be … Continue reading

Posted in Advisory Committee Prepapartion, Current Affairs | Comments Off on Principles for COVID-19 Healthcare Communications – 2 – The Virtual Medical Meeting

Impact of COVID-19 on Regulatory Enforcement and Approvals – Part 2

Earlier this month I published a blog posting that raised questions related to the potential for disruption of approvals in the wake of FDA actions to limit inspections due to the COVID-19 pandemic. Subsequently I had the opportunity to pose … Continue reading

Posted in Advisory Committee Prepapartion, Approval Announcements, Current Affairs, FDA Policy | Tagged , | 14 Comments